Alon Barsheshet

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5850934/publications.pdf

Version: 2024-02-01

65 papers 1,640 citations

279798 23 h-index 302126 39 g-index

66 all docs

66 docs citations

66 times ranked 2944 citing authors

#	Article	IF	CITATIONS
1	Impact of Valve Size on Paravalvular Leak and Valve Hemodynamics in Patients With Borderline Size Aortic Valve Annulus. Frontiers in Cardiovascular Medicine, 2022, 9, 847259.	2.4	2
2	Improved immunogenicity following the third dose of BNT162b2 mRNA vaccine in heart transplant recipients. European Journal of Cardio-thoracic Surgery, 2022, 62, .	1.4	3
3	Short membranous septum length in bicuspid aortic valve stenosis increases the risk of conduction disturbances. Journal of Cardiovascular Computed Tomography, 2021, 15, 339-347.	1.3	24
4	Long Term Outcomes of Patients Treated With Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2021, 141, 72-78.	1.6	4
5	Epicardial fat and the risk of atrial tachy-arrhythmia recurrence post pulmonary vein isolation: a computed tomography study. International Journal of Cardiovascular Imaging, 2021, 37, 2785-2790.	1.5	8
6	Comparison of Low and Full Dose Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Renal Dysfunction (from a National Registry). American Journal of Cardiology, 2021, 159, 87-93.	1.6	1
7	Safety of High-Dose Dabigatran in Elderly and Younger Patients with a Low Bleeding Risk: A Prospective Observational Study. Cardiology, 2021, 146, 641-645.	1.4	1
8	Effect of fibrotic capsule debridement during generator replacement on cardiac implantable electronic device infection risk. Journal of Interventional Cardiac Electrophysiology, 2020, 58, 113-118.	1.3	8
9	Applicability of the MADIT-CRT Response Score for Prediction of Long-Term Clinical and Arrhythmic Events by QRS Morphology. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e008499.	4.8	1
10	Periprocedural Anticoagulation Interruption Strategies for Ablation of Atrial Fibrillation: What Is the Best Current Practice?. Cardiology, 2020, 145, 682-684.	1.4	0
11	Predicting the risk of late futile outcome after transcatheter aortic valve implantation. Catheterization and Cardiovascular Interventions, 2020, 96, E695-E702.	1.7	4
12	Validation of cardiac damage classification and addition of albumin in a large cohort of patients undergoing transcatheter aortic valve replacement. International Journal of Cardiology, 2020, 304, 23-28.	1.7	10
13	Liver steatosis is a major predictor of poor outcomes in chronic hepatitis C patients with sustained virological response. Journal of Viral Hepatitis, 2019, 26, 1257-1265.	2.0	32
14	Liver steatosis is a strong predictor of mortality and cancer in chronic hepatitis B regardless of viral load. JHEP Reports, 2019, 1, 9-16.	4.9	52
15	Risk of death without appropriate defibrillator shock in patients with advanced renal dysfunction. Europace, 2019, 21, 459-464.	1.7	4
16	Transcatheter Aortic Valve Replacement in Oncology Patients With Severe AorticÂStenosis. JACC: Cardiovascular Interventions, 2019, 12, 78-86.	2.9	53
17	Temporal Trends in Gender-Related Differences and Outcomes in Patients Who Underwent Transcatheter Aortic Valve Implantation (from the Israeli Transcatheter Aortic Valve Implantation) Tj ETQq1 1 C).7843 <u>4</u> 34 rg	gBT 10 verloce
18	Long-Term Survival With Implantable Cardioverter-Defibrillator in Different Symptomatic Functional Classes of Heart Failure. American Journal of Cardiology, 2018, 121, 615-620.	1.6	10

#	Article	IF	Citations
19	Relation of Left Ventricular Fractional Shortening to Needfor Permanent Pacemaker After Transcatheter AorticValve Implantation. American Journal of Cardiology, 2018, 122, 833-837.	1.6	3
20	Prognostic significance of aortic valve gradient in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Catheterization and Cardiovascular Interventions, 2017, 90, 1175-1182.	1.7	5
21	Predictors of 1-Year Mortality After Transcatheter Aortic Valve Implantation in Patients With and Without Advanced Chronic Kidney Disease. American Journal of Cardiology, 2017, 120, 2025-2030.	1.6	18
22	Anemia and the Risk of Life-threatening Ventricular Tachyarrhythmias from the Israeli Implantable Cardioverter Defibrillator Registry. American Journal of Cardiology, 2017, 120, 2187-2192.	1.6	5
23	Contemporary rates and outcomes of single- vs. dual-coil implantable cardioverter defibrillator lead implantation: data from the Israeli ICD Registry. Europace, 2017, 19, 1485-1492.	1.7	11
24	Temporal trends in transcatheter aortic valve implantation, 2008–2014: patient characteristics, procedural issues, and clinical outcome. Clinical Cardiology, 2017, 40, 82-88.	1.8	29
25	Admission blood glucose and 10-year mortality among patients with or without pre-existing diabetes mellitus hospitalized with heart failure. Cardiovascular Diabetology, 2017, 16, 102.	6.8	22
26	Study of the wearable cardioverter defibrillator in advanced heartâ€failure patients (SWIFT). Journal of Cardiovascular Electrophysiology, 2017, 28, 778-784.	1.7	17
27	Syncope in Primary Prevention Implantable Cardioverter Defibrillator Implantation. Israel Medical Association Journal, 2017, 19, 15-18.	0.1	0
28	Relationship between age and inappropriate implantable cardioverter-defibrillator therapy in MADIT-RIT (Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy). Heart Rhythm, 2016, 13, 888-893.	0.7	10
29	Impact of Renal Dysfunction on Results of Transcatheter Aortic Valve Replacement Outcomes in a Large Multicenter Cohort. American Journal of Cardiology, 2016, 118, 1888-1896.	1.6	37
30	Characteristics and outcomes of diabetic patients with an implantable cardioverter defibrillator in a real world setting: results from the Israeli ICD registry. Cardiovascular Diabetology, 2016, 15, 160.	6.8	5
31	The wearable cardioverter defibrillator as a bridge to implantable defibrillator post myocardial infarction: what do we know?. Expert Review of Medical Devices, 2016, 13, 627-632.	2.8	O
32	Time Dependence of VentricularÂTachyarrhythmias AfterÂMyocardial Infarction. JACC: Clinical Electrophysiology, 2016, 2, 565-573.	3.2	0
33	Mortality prediction following transcatheter aortic valve replacement: A quantitative comparison of risk scores derived from populations treated with either surgical or percutaneous aortic valve replacement. The Israeli TAVR Registry Risk Model Accuracy Assessment (IRRMA) study. International lournal of Cardiology. 2016, 215, 227-231.	1.7	36
34	Type of Atrial Fibrillation and Clinical Outcomes in Patients Undergoing Transcatheter Aortic Valve Replacement. Annals of Noninvasive Electrocardiology, 2016, 21, 519-525.	1.1	9
35	Relative Wall Thickness and the Risk for Ventricular Tachyarrhythmias in Patients With Left Ventricular Dysfunction. Journal of the American College of Cardiology, 2016, 67, 303-312.	2.8	46
36	Cardiac Resynchronization in Different Age Groups: A MADIT-CRT Long-Term Follow-Up Substudy. Journal of Cardiac Failure, 2016, 22, 143-149.	1.7	9

#	Article	IF	CITATIONS
37	Early intervention and longâ€ŧerm outcome with cardiac resynchronization therapy in patients without a history of advanced heart failure symptoms. European Journal of Heart Failure, 2015, 17, 964-970.	7.1	11
38	Reduced risk of lifeâ€threatening ventricular tachyarrhythmias with cardiac resynchronization therapy: relationship to left ventricular ejection fraction. European Journal of Heart Failure, 2015, 17, 971-978.	7.1	23
39	Effects of Statins on First and Recurrent Supraventricular Arrhythmias in Patients With Mild Heart Failure (from the Multicenter Automatic Defibrillator Implantation Trial With Cardiac) Tj ETQq1 1 0.784314 rgBT	О ме rlock 1	₲ Tf 50 657
40	Inverse Relationship of Blood Pressure to Long-Term Outcomes and Benefit of Cardiac Resynchronization Therapy in Patients With Mild Heart Failure. Circulation: Heart Failure, 2015, 8, 921-926.	3.9	10
41	Outcomes of Patients at Estimated Low, Intermediate, and High Risk Undergoing Transcatheter Aortic Valve Implantation for Aortic Stenosis. American Journal of Cardiology, 2015, 116, 1916-1922.	1.6	43
42	Comparison of Age (<75ÂYears Versus â%¥75ÂYears) to Risk of Ventricular Tachyarrhythmias and Implantable Cardioverter Defibrillator Shocks (from the Multicenter Automatic Defibrillator) Tj ETQq0 0 0 rgBT /Ov 114, 1855-1860.	verlock 10	Tf 50 542 To
43	Predictors of Spontaneous Reverse Remodeling in Mild Heart Failure Patients With Left Ventricular Dysfunction. Circulation: Heart Failure, 2014, 7, 565-572.	3.9	24
44	Congenital Long QT Syndromes: Prevalence, Pathophysiology and Management. Paediatric Drugs, 2014, 16, 447-456.	3.1	28
45	Comparison of Low Versus High (>40Âmm Hg) Pulse Pressure to Predict the Benefit of Cardiac Resynchronization Therapy for Heart Failure (from the Multicenter Automatic Defibrillator) Tj ETQq1 1 0.784314 r 1053-1058.	gBŢ/Overl	ock 10 Tf 5(
46	Genotypeâ€Specific Risk Stratification and Management of Patients with Long QT Syndrome. Annals of Noninvasive Electrocardiology, 2013, 18, 499-509.	1.1	37
47	Sex-related differences in patients' responses to heart failure therapy. Nature Reviews Cardiology, 2012, 9, 234-242.	13.7	31
48	Applicability of a Risk Score for Prediction of the Long-Term (8-Year) Benefit of the Implantable Cardioverter-Defibrillator. Journal of the American College of Cardiology, 2012, 59, 2075-2079.	2.8	137
49	Atrial Burst Pacing with Biphasic and Monophasic Waveforms for Atrial Fibrillation. Annals of Noninvasive Electrocardiology, 2012, 17, 22-27.	1.1	1
50	Reverse Remodeling and the Risk of Ventricular Tachyarrhythmias in the MADIT-CRT (Multicenter) Tj ETQq0 0 0 rg American College of Cardiology, 2011, 57, 2416-2423.	BT /Overlo	ck 10 Tf 50 : 200
51	Genotype-specific QT correction for heart rate and the risk of life-threatening cardiac events in adolescents with congenital long-QT syndrome. Heart Rhythm, 2011, 8, 1207-1213.	0.7	22
52	Long-term implications of cumulative right ventricular pacing among patients with an implantable cardioverter-defibrillator. Heart Rhythm, 2011, 8, 212-218.	0.7	78
53	Effect of Elapsed Time From Coronary Revascularization to Implantation of a Cardioverter Defibrillator on Long-Term Survival in the MADIT-II Trial. Journal of Cardiovascular Electrophysiology, 2011, 22, 1237-1242.	1.7	22
54	Relation of Bundle Branch Block to Long-Term (Four-Year) Mortality in Hospitalized Patients With Systolic Heart Failure. American Journal of Cardiology, 2011, 107, 540-544.	1.6	54

#	Article	IF	CITATION
55	Genetics of Sudden Cardiac Death. Current Cardiology Reports, 2011, 13, 364-376.	2.9	27
56	Risk of Syncope in Family Members Who Are Genotype-Negative for a Family-Associated Long-QT Syndrome Mutation. Circulation: Cardiovascular Genetics, 2011, 4, 491-499.	5.1	9
57	Time-dependent benefit of preventive cardiac resynchronization therapy after myocardial infarction. European Heart Journal, 2011, 32, 1614-1621.	2.2	11
58	Response to preventive cardiac resynchronization therapy in patients with ischaemic and nonischaemic cardiomyopathy in MADIT-CRT. European Heart Journal, 2011, 32, 1622-1630.	2.2	128
59	Predictors of longâ€ŧerm (4â€year) mortality in elderly and young patients with acute heart failure. European Journal of Heart Failure, 2010, 12, 833-840.	7.1	57
60	Time dependence of life-threatening ventricular tachyarrhythmias after coronary revascularization in MADIT-CRT. Heart Rhythm, 2010, 7, 1421-1427.	0.7	25
61	Effect of Bundle Branch Block Patterns on Mortality in Hospitalized Patients With Heart Failure. American Journal of Cardiology, 2008, 101, 1303-1308.	1.6	21
62	Whole-body hyperthermia attenuates experimental autoimmune myocarditis in the rat. Cardiovascular Pathology, 2008, 17, 375-381.	1.6	3
63	The Effects of External Counter Pulsation Therapy on Circulating Endothelial Progenitor Cells in Patients with Angina Pectoris. Cardiology, 2008, 110, 160-166.	1.4	27
64	Acute ST Elevation Myocardial Infarction during Intravenous Immunoglobulin Infusion. Annals of the New York Academy of Sciences, 2007, 1110, 315-318.	3.8	9
65	Admission Blood Glucose Level and Mortality Among Hospitalized Nondiabetic Patients With Heart Failure. Archives of Internal Medicine, 2006, 166, 1613.	3.8	90